STOCK TITAN
  1. Home
  2. News
  3. IONS

Ionis Pharmaceuticals, Inc. - IONS STOCK NEWS

Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a leading biotechnology company headquartered in Carlsbad, California. Founded in 1989, Ionis has been pioneering the discovery and development of antisense drugs, with an impressive portfolio of over 1300 patents. Ionis focuses on creating innovative RNA-targeted therapies for complex diseases, particularly in the areas of cardiovascular, metabolic, neurological, and rare genetic disorders.

Ionis has successfully brought several groundbreaking medicines to market. Notable achievements include the development of Spinraza, in collaboration with Biogen, which was launched in 2016 to treat spinal muscular atrophy, a rare neuromuscular disorder. In 2023, Biogen also launched Qalsody for ALS, further extending the impact of Ionis' antisense technology.

Through its cardiovascular-focused subsidiary, Akcea Therapeutics, Ionis has introduced drugs like Tegsedi for ATTR amyloidosis and Waylivra in Europe for cardiology indications. The company continues to advance its pipeline with promising candidates such as olezarsen, an investigational RNA-targeted therapy for familial chylomicronemia syndrome (FCS). Ionis' ongoing Phase 3 trials for olezarsen have shown promising results, with significant reductions in triglyceride levels and improvements in related health outcomes.

Ionis' commitment to innovation and patient care is also evident in its robust financial health and strategic partnerships. With a deep understanding of disease biology and cutting-edge technology, Ionis continues to drive advancements in RNA therapies and gene editing, aiming to deliver life-changing medicines for patients around the world.

Recently, Ionis announced positive clinical trial results for several of its investigational drugs and plans to pursue regulatory approvals for these therapies. The company's pipeline is well-positioned to address unmet medical needs in various therapeutic areas, promising a steady flow of new treatments in the coming years.

For more detailed information about Ionis Pharmaceuticals, its products, and career opportunities, visit their official website at www.ionispharma.com.

News

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Rhea-AI Summary
Vect-Horus, a biotechnology company, has entered into a global license agreement with Ionis Pharmaceuticals, Inc. The agreement provides Ionis with an exclusive license for a specified number of targets using Vect-Horus’ platform technology for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier. Vect-Horus will receive a double-digit million-dollar upfront payment, development, regulatory, and commercial milestone payments, and tiered single digit royalties on annual product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News

Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema

Rhea-AI Summary
Ionis Pharmaceuticals, Inc. announced positive Phase 3 OASIS-HAE study results for donidalorsen in treating hereditary angioedema, meeting primary endpoint with significant reduction in attack rate, favorable safety profile, and plans for FDA and EMA submissions. Donidalorsen targets prekallikrein to interrupt HAE attacks, with plans for independent drug launches and presentations of Phase 3 results at medical congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
clinical trial
-
News

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases

Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced their 2023 achievements and previewed important milestones for 2024, including U.S. approval of WAINUA™ and QALSODY® for serious diseases, positive Phase 3 trial readouts, and expansion of their late-stage pipeline to nine medicines in Phase 3 trials for 11 potential indications. They also made advances in their technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
News

Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)

Rhea-AI Summary
Alcyone Therapeutics Inc. (Alcyone) announced the first patient implanted in the PIERRE pivotal study to evaluate the safety and performance of the ThecaFlex DRx System (ThecaFlex) subcutaneous port and intrathecal catheter system for repeat intrathecal access, cerebrospinal fluid (CSF) aspiration, and delivery of SPINRAZA® (nusinersen) in spinal muscular atrophy (SMA) patients. The ThecaFlex device has the potential to significantly benefit patients with SMA who are being treated with SPINRAZA and are resistant to lumbar punctures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
clinical trial
-
News

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced FDA approval of WAINUA™ (eplontersen) for the treatment of hATTR-PN in adults. WAINUA demonstrated consistent and sustained benefit in halting neuropathy disease progression and improving quality of life. It will be available in the U.S. in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
-
News

Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) CEO to present company overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.94%
Tags
conferences
News

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. to exclusively commercialize donidalorsen in Europe for hereditary angioedema (HAE). Ionis will independently bring donidalorsen to U.S. patients if approved, with Phase 3 results expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
News

Ionis announces the appointment of Michael Yang to Board of Directors

Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has appointed Michael Yang, an experienced biopharmaceutical executive, to its Board of Directors, expanding the total number of members to 10. Mr. Yang has over 20 years of leadership experience in biotech, pharmaceutical, and medical device companies, with significant achievements in launching new platforms, expanding global revenues, and diversifying product lines. His most recent role was as President, CEO, and Board member of ViaCyte, which was acquired by Vertex in 2022. Ionis' CEO, Brett P. Monia, and Board Chairman, Joseph Loscalzo, M.D., Ph.D., expressed excitement about Michael's appointment, highlighting his deep biopharmaceutical leadership experience and strong patient focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
management
-
News

Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome

Rhea-AI Summary
IONIS: Part 1 of HALOS trial for ION582 in Angelman syndrome completes enrollment with positive preliminary findings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema

Rhea-AI Summary
IONIS Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of donidalorsen, showing a sustained 96% reduction in hereditary angioedema attacks over two years. Patients reported improved quality of life. Phase 3 results are expected in H1 2024. The drug received orphan drug designation in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
clinical trial

FAQ

What is the current stock price of Ionis Pharmaceuticals (IONS)?

The current stock price of Ionis Pharmaceuticals (IONS) is $34.34 as of November 15, 2024.

What is the market cap of Ionis Pharmaceuticals (IONS)?

The market cap of Ionis Pharmaceuticals (IONS) is approximately 5.2B.

What does Ionis Pharmaceuticals specialize in?

Ionis Pharmaceuticals specializes in the discovery and development of antisense drugs to treat complex diseases, focusing on cardiovascular, metabolic, neurological, and rare diseases.

Where is Ionis Pharmaceuticals located?

Ionis Pharmaceuticals is headquartered in Carlsbad, California.

What are some key products developed by Ionis Pharmaceuticals?

Key products include Spinraza for spinal muscular atrophy, Qalsody for ALS, Tegsedi for ATTR amyloidosis, and Waylivra for cardiology in Europe.

What is the latest development in Ionis' pipeline?

Ionis is advancing olezarsen, an investigational therapy for familial chylomicronemia syndrome, which has shown promising Phase 3 trial results.

Who are some of Ionis' key partners?

Ionis has strategic partnerships with companies like Biogen and AstraZeneca, helping to bring their innovative therapies to market.

How does Ionis Pharmaceuticals contribute to RNA therapy innovation?

Ionis is a pioneer in RNA-targeted therapies, driving advancements in antisense technology and gene editing to develop treatments for serious diseases.

What is olezarsen and what does it treat?

Olezarsen is an RNA-targeted investigational medicine being developed to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels.

How can I learn more about career opportunities at Ionis Pharmaceuticals?

Visit the Ionis Pharmaceuticals website at www.ionispharma.com for more information on career opportunities and to apply for open positions.

What recent clinical trials has Ionis Pharmaceuticals announced?

Ionis recently announced positive results from trials involving olezarsen for FCS and donidalorsen for hereditary angioedema, among others.

How does Ionis Pharmaceuticals support patients with rare diseases?

Ionis develops targeted therapies for rare diseases, providing innovative treatments where few or no options previously existed, significantly improving patient outcomes.

Stock IONS logo
Ionis Pharmaceuticals, Inc.

Nasdaq:IONS

IONS Rankings

#1265 Ranked by Market Cap
N/A Ranked by Dividends

IONS Stock Data

5.19B
145.97M
0.78%
99.5%
6.26%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CARLSBAD